Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics, Inc. in the Healthcare sector is trading at $0.89 with a market capitalization of $43M. Wall Street consensus targets $7.00 (3 analysts), implying a +682.5% move over the next 12 months. The stock is currently near its 52-week low of $0.86, remaining 33.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.